Genmab — August 2020
-
Det er ret fedt, at høre den competitive edge fra GEN
-
Judith ser TF target som proof of concept for andre programmer
-
Inkluderer 4 yderligere tumor targets
-
Cannot provide commitment
-
Men kommer i future
-
Spændende for TF programmet
-
Dara har 24% patient share - driven by earlier patient uptake
-
1st line 3 fold uptake
-
135k patients treated dara
-
9% 1st line
-
42% 2st line
-
op fra 3% og 34%
-
Der er ikke meget “flavour” på judiths svar
-
Tak troldmand
-
Epco - expedited path?
-
Hun er lidt af en våd klud i sine svar
-
Judith altså
-
Hvis alle var som hende, var der ikke megen grund til overhovedet at lytte med
-
De taler om, hvordan man lukker gap’et til Roche på eco
-
Nu stepper jan ind
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind